Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Jivi Market Expansion From $ Billion In 2026 To $ Billion In 2030
Growth during the historic period was driven by recurring bleeding episodes in hemophilia A, the shortcomings of conventional factor VIII treatments, the early uptake of recombinant factor products, an emphasis on preventing joint deterioration, and the expansion of hemophilia treatment centers.
The forecast period’s expansion is fueled by heightened reliance on long-acting clotting factors, broader availability of home infusion services, enhanced pediatric hemophilia care coverage, favorable reimbursement frameworks, and advances in recombinant therapy development. Key developments shaping this outlook encompass the rising uptake of extended half-life factor VIII, a transition toward preventive hemophilia treatment, patient-driven demand for fewer injections, growth in home-centered hemophilia care delivery, and better therapy compliance outcomes.
Download A Free Sample Report For Comprehensive Market Insights:
Jivi Market Growth Drivers: What Factors Are Accelerating Expansion?
The growing incidence of hemophilia is anticipated to drive expansion in the jivi market moving forward. This condition results from genetic mutations in X-linked genes responsible for producing clotting factors, causing a deficiency or dysfunction of factor VIII (hemophilia A) or factor IX (hemophilia B), which compromises the blood’s clotting ability. The rising number of hemophilia cases is linked to enhanced diagnostic methods, greater disease awareness, and more comprehensive global reporting. Jivi supports hemophilia patients by supplying a long-acting recombinant factor VIII replacement that facilitates blood clotting to prevent or manage bleeding episodes, while its prolonged half-life decreases the need for frequent injections, improving patient comfort and treatment compliance. For example, in April 2025, Hemophilia News Today, a US-based medical news outlet, reported that the global population of individuals with hemophilia was estimated at around 836,000, with approximately 284,000 suffering from the severe form. Consequently, the increasing prevalence of hemophilia is fueling the jivi market’s growth.
The growing emphasis on personalized medicine is set to boost the jivi market in the coming years. Personalized medicine refers to a healthcare approach that tailors treatments and interventions based on an individual’s genetic profile, environmental factors, and lifestyle choices. This approach is gaining traction due to progress in genomic science, a rising burden of chronic illnesses, enhanced diagnostic capabilities, and a shift toward patient-focused care. Jivi contributes to personalized medicine by enabling customized therapy for hemophilia A patients, as its extended half-life allows for flexible dosing schedules adapted to individual needs, thereby improving adherence and lowering the frequency of bleeding events. In February 2024, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, noted that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to six in 2022. Hence, the heightened focus on personalized medicine is propelling the jivi market forward.
Growing investments in research and development are expected to speed up the growth of the jivi market. These investments are driven by the demand for novel therapies that address unmet medical requirements, boost treatment effectiveness, and improve patient outcomes across various therapeutic fields. R&D efforts focused on Jivi aim to refine its efficacy, safety profile, and user convenience by extending its half-life, allowing for less frequent administration, and enhancing patient adherence, while also advancing personalized medicine approaches for customized treatment regimens. In December 2024, Focus2030, a France-based civil society organization, highlighted that Gavi’s 2026-2030 Investment Opportunity calls for $9 billion, including $1.7 billion for the International Finance Facility for Immunization, to vaccinate an additional 500 million children by 2030, potentially saving 8 to 9 million lives. Therefore, rising research and development investments are driving the jivi market’s expansion.
Jivi Market Segment Analysis And Revenue Opportunities
The jivi market covered in this report is segmented –
1) By Formulation: Lyophilized Powder For Reconstitution, Ready-to-use Formulations
2) By Route of Administration: Intravenous, Subcutaneous
3) By Indication: Treatment Of Hemophilia A, Prophylaxis, On-demand Treatment For Bleeding Episodes
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies
5) By End Use: Hospitals, Hemophilia Treatment Centres, Specialty Clinics, Home Healthcare Settings
Jivi Market Leading Players Shaping Industry Direction
Major companies operating in the jivi market are Bayer AG
Access The Complete Jivi Market Report:
Jivi Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the jivi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the jivi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model